Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Lincy LalSujit S Sansgiry

Abstract

The objective of this study was to assess the impact of a new evidence-based institutional practice algorithm on the patterns and costs of treatment of chemotherapy-induced anemia (CIA) in lymphoma patients prescribed erythropoietic-stimulating agents (ESAs). The study design was retrospective, with a historical control group. Patient demographic data, clinical data (including chemotherapy and hemoglobin values), and cost data were extracted from patient medical charts and institutional databases. Descriptive statistics, t tests, and chi-square analyses were conducted to evaluate the study objectives. The study population consisted of 154 patients, 90 patients in the pre-implementation group and 64 in the post-implementation group. Both groups had similar demographic and baseline clinical characteristics. After implementation, there was a significant decrease in the mean hemoglobin level at the time of subsequent ESA dosing from 9.59 to 8.98 g/dL (P < 0.0001). The proportion of patients who received an ESA at a hemoglobin level >10 g/dL decreased significantly from 66% to 17% (P < 0.0001). There was no significant difference in the mean hemoglobin level at week 4 of ESA therapy, which may indicate that patients were not clinica...Continue Reading

References

Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J GlaspyS Vadhan-Raj
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J LittlewoodUNKNOWN Epoetin Alfa Study Group
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L GabriloveL H Einhorn
Aug 22, 2002·Journal of the National Cancer Institute·Johan VansteenkisteUNKNOWN Aranesp 980297 Study Group
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Douglas RizzoUNKNOWN American Society of Clinical Oncology. American Society of Hematology
Apr 3, 2003·British Journal of Cancer·M BoogaertsUNKNOWN Epoetin beta QOL Working Group
Jul 25, 2003·British Journal of Haematology·Michael HedenusUNKNOWN Darbepoetin Alfa 20000161 Study Group
Sep 6, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D KotasekUNKNOWN Aranesp 980291 Study Group
Sep 29, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigRoscoe F Morton
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian Leyland-JonesEls Vercammen
Feb 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James R WrightMark N Levine
Jun 15, 2007·The New England Journal of Medicine·Robert Steinbrook
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Vinni JunejaRichard Pazdur
Dec 25, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Venturino, G Colloca

❮ Previous
Next ❯

Citations

Sep 22, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Elizabeth TarlovDenise M Hynes
Oct 26, 2013·Future Oncology·Juan Carlos BertoglioGiovanna Petrangolini
Jan 27, 2016·The Journal of Urology·Ronac MamtaniBen Boursi
Mar 14, 2019·Diabetes Care·Anuradhaa SubramanianKrishnarajah Nirantharakumar
May 17, 2013·Epidemiology·Lucía Cea-SorianoLuis A García Rodríguez
Sep 1, 2018·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Uchenna AnyanwaguIskandar Idris
May 18, 2016·Annals of the Rheumatic Diseases·Devyani MisraYuqing Zhang
Dec 19, 2013·PloS One·Sarah HardoonDavid P J Osborn
Feb 14, 2014·Birth Defects Research. Part A, Clinical and Molecular Teratology·Rachel SokalKate M Fleming
May 7, 2014·Pharmacoepidemiology and Drug Safety·Lucia Cea SorianoSonia Hernández-Díaz
Jun 26, 2014·PloS One·Elisa Martín-MerinoLuis Alberto García-Rodríguez
Sep 25, 2014·Pharmacoepidemiology and Drug Safety·Lucía Cea SorianoLuis Alberto García Rodríguez
Nov 16, 2014·Archives of Disease in Childhood·Ruth BakerDenise Kendrick
Jan 28, 2015·Pharmacoepidemiology and Drug Safety·Kristina StarI Ralph Edwards
Oct 8, 2014·BJOG : an International Journal of Obstetrics and Gynaecology·L BanL J Tata
Feb 3, 2016·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Joseph F HayesDavid P J Osborn
Jun 25, 2016·Annals of the Rheumatic Diseases·Yuqing ZhangHyon K Choi
Mar 1, 2018·The Journal of Antimicrobial Chemotherapy·F Christiaan K DolkTimo Smieszek
Mar 1, 2018·The Journal of Antimicrobial Chemotherapy·Koen B PouwelsJulie V Robotham
Mar 1, 2018·The Journal of Antimicrobial Chemotherapy·Koen B PouwelsTimo Smieszek
Nov 30, 2016·Annals of the Rheumatic Diseases·Rennie L RheeGunnar Tomasson
Oct 12, 2019·The European Respiratory Journal·Alexandra L DimaUNKNOWN Members of the ASTRO-LAB group were:
Nov 15, 2019·Journal of Psychopharmacology·Juan Carlos Bazo-AlvarezIrene Petersen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

© 2021 Meta ULC. All rights reserved